Tango Net Income From Continuing Ops from 2010 to 2024

TNGX Stock  USD 3.10  0.16  5.44%   
Tango Therapeutics Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss will likely drop to about -105 M in 2024. During the period from 2010 to 2024, Tango Therapeutics Net Loss regression line of annual values had significance of  0 and arithmetic mean of (62,879,137). View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-100 M
Current Value
-105 M
Quarterly Volatility
21.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Tango Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tango Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.6 M, Interest Expense of 3.6 M or Selling General Administrative of 22.1 M, as well as many indicators such as Price To Sales Ratio of 19.37, Dividend Yield of 0.0 or PTB Ratio of 6.45. Tango financial statements analysis is a perfect complement when working with Tango Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Tango Therapeutics Correlation against competitors.
For more information on how to buy Tango Stock please use our How to Invest in Tango Therapeutics guide.

Latest Tango Therapeutics' Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Tango Therapeutics over the last few years. It is Tango Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tango Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

Tango Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(62,879,137)
Coefficient Of Variation(34.38)
Mean Deviation16,616,352
Median(51,972,000)
Standard Deviation21,614,802
Sample Variance467.2T
Range56.2M
R-Value(0.71)
Mean Square Error246.8T
R-Squared0.51
Significance0
Slope(3,449,941)
Total Sum of Squares6540.8T

Tango Net Income From Continuing Ops History

2024-105 M
2023-100 M
2022-108.2 M
2021-58.2 M

About Tango Therapeutics Financial Statements

Tango Therapeutics investors use historical fundamental indicators, such as Tango Therapeutics' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Tango Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-100 M-105 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Tango Stock Analysis

When running Tango Therapeutics' price analysis, check to measure Tango Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tango Therapeutics is operating at the current time. Most of Tango Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tango Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tango Therapeutics' price. Additionally, you may evaluate how the addition of Tango Therapeutics to your portfolios can decrease your overall portfolio volatility.